Why the study?
Heart failure involves complex mechanisms requiring a multimarker strategy, prompting the evaluation of a targeted MRM mass spectrometry workflow to monitor disease and stratify risk.
Case-Control (n=30)
No
A targeted proteomic approach identified a 4-protein plasma biomarker panel that differentiates heart failure severity and distinguishes patients with reduced ejection fraction from healthy individuals.
Four-protein panel supports targeted proteomics for HF discrimination; hypothesis-generating and requires larger prospective validation before any clinical use.
Heart failure (HF) is a complex disease due to the intricate interplay of several mechanisms, which therefore implies the need for a multimarker strategy to better personalize the care of patients with HF. In this study, we developed a targeted mass spectrometry approach based on multiple reaction monitoring (MRM) to measure multiple circulating protein biomarkers, involved in cardiovascular disease, to address their relevance in the human HF, intending to assess the feasibility of the workflow in the disease monitoring and risk stratification. In this study, we analyzed a total of 60 plasma proteins in 30 plasma samples from eight control subjects and 22 age- and gender- matched HF patients. We identified a panel of four plasma proteins, namely Neuropilin-2, Beta 2 microglobulin, alpha-1-antichymotrypsin, and complement component C9, that were more abundant in HF patients in relation to disease severity and pulmonary dysfunction. Moreover, we showed the ability of the combination of these candidate proteins to discriminate, with sufficient accuracy, HF patients from healthy subjects. In conclusion, we demonstrated the feasibility and potential of a proteomic workflow based on MRM mass spectrometry for the evaluation of multiple proteins in human plasma and the identification of a panel of biomarkers of HF severity.
No takes yet. Share an insight, caveat, or question.
Brioschi et al. (2021) conducted a case-control in Heart Failure with reduced Ejection Fraction (n=30). Plasma protein biomarker panel (NRP2, B2M, A1AC, C9) vs. Healthy controls was evaluated on Diagnostic discrimination of heart failure from healthy subjects (AUC 0.835).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: